Table 1

 Baseline characteristics of liver transplant recipients with ursodeoxycholic acid (UDCA) therapy and controls

CharacteristicUDCA group (n = 14)Placebo group (n = 12)p Value*
Data are expressed as mean (SD).
ALK PH, alkaline phosphatase; ALT, alanine aminotransferase; AST, aspartate aminotransferase; AzA, azathioprine; CyA, ciclosporin; OLT, orthotopic liver transplantation.
*t test or Fisher’s exact test as appropriate.
Age (y)56.3 (12.6)50.7 (15.7)0.3
Sex (M:F)7:76:6NS
OLT indications (%)
    Cryptogenic725
    Cholestatic368
    Alcoholic368
    Autoimmune1417
    Miscellaneous742
No of previous rejections0 (1)0 (1)NS
Time since OLT (months)51.8 (12.8)60.2 (29.2)0.3
Biochemistry
    ALT (U/l)18.8 (8.7)29.9 (29.5)0.1 (4–26)
    AST (U/l)23.8 (9.5)32.8 (20.3)0.1 (5–27)
    ALK PH (U/l)93.1 (25.2)123 (50.6)0.08 (16–98)
    Bilirubin (μmol/l)12.4 (4.5)15.2 (6.6)0.2 (3.4–17.1)
    Creatinine (μmol/l)144.1 (55.7)163.6 (60.3)0.3 (71–168)
Immunosuppression
    CyA dose (mg twice daily)128 (42.6)139.58)0.6
    CyA level (ng/ml)130.3 (68)172.5 (50)0.1
RegimensNS
    CyA+AzAn = 8n = 6
    CyA+prednisonen = 2n = 3
    CyA alonen = 4n = 3